IVA Company Profile and Key Details
Inventiva SA
Price Chart
Stock Price Today
Inventiva S.A. (IVA) stock surged +0.87%, trading at $4.64 on NASDAQ, up from the previous close of $4.60. The stock opened at $4.59, fluctuating between $4.52 and $4.66 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 27, 2026 | 4.45 | 4.68 | 4.43 | 4.60 | 704.67K |
| Jul 24, 2026 | 4.44 | 4.55 | 4.38 | 4.46 | 667.37K |
| Jul 23, 2026 | 4.42 | 4.55 | 4.39 | 4.51 | 636.79K |
| Jul 22, 2026 | 4.47 | 4.61 | 4.31 | 4.54 | 523.34K |
| Jul 21, 2026 | 4.38 | 4.53 | 4.36 | 4.48 | 816.76K |
| Jul 20, 2026 | 4.70 | 4.71 | 4.39 | 4.42 | 773.36K |
| Jul 17, 2026 | 4.60 | 4.68 | 4.49 | 4.62 | 862.36K |
| Jul 16, 2026 | 4.46 | 4.62 | 4.39 | 4.52 | 869.1K |
| Jul 15, 2026 | 4.39 | 4.57 | 4.31 | 4.47 | 984.95K |
| Jul 14, 2026 | 4.28 | 4.50 | 4.28 | 4.40 | 1.29M |
| Jul 13, 2026 | 4.31 | 4.52 | 4.21 | 4.30 | 734.73K |
| Jul 10, 2026 | 4.50 | 4.51 | 4.25 | 4.30 | 571.68K |
| Jul 09, 2026 | 4.33 | 4.55 | 4.20 | 4.53 | 1.78M |
| Jul 08, 2026 | 4.27 | 4.74 | 4.20 | 4.39 | 3.4M |
| Jul 07, 2026 | 3.87 | 4.61 | 3.76 | 4.56 | 3.29M |
| Jul 06, 2026 | 3.92 | 4.00 | 3.82 | 3.90 | 3M |
| Jul 02, 2026 | 3.70 | 3.97 | 3.67 | 3.91 | 1.83M |
| Jul 01, 2026 | 3.75 | 3.79 | 3.53 | 3.69 | 1.71M |
| Jun 30, 2026 | 3.59 | 3.80 | 3.54 | 3.78 | 2.1M |
| Jun 29, 2026 | 3.53 | 3.56 | 3.45 | 3.55 | 1.19M |
Contact Details
About Company
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Company Information
| Employees | 77 |
| Beta | 0.89 |
| Sales or Revenue | $17.48M |
| 5Y Sales Change% | 1.476% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer & Director
Ms. Nathalie Harroy
Head of HR
Dr. Irena Konstantinova
Head of Biology & Pharmacology
Dr. Michael Cooreman
Chief Medical Officer
Mr. Jean Volatier
Chief Financial Officer
Mr. Jean-Paul Dutertre M.D.
Head of Pharmacovigilance
Mr. Eric Duranson L.L.M.
Gen. Counsel
Mr. Frederic Cren
Co-Founder, Chief Executive Officer & Chairman
Alice Roudot-Ketelers Pharm.D.
Chief Operating Officer
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep